quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·38d
PRRelease
Mirum Pharmaceuticals Inc. logo

Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases

MIRM· Mirum Pharmaceuticals Inc.
Health Care
Original source

Companies

  • MIRM
    Mirum Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Feb 18UpdateRBC Capital Mkts$130.00
  • Sep 24UpdateTD Cowen$95.00
  • Aug 11UpdateStifel$89.00
  • May 19UpdateH.C. Wainwright$73.00
  • Apr 17UpdateStifel$48.00
  • Dec 18UpdateH.C. Wainwright$58.00

Related

  • SEC10h
    SEC Form DEFA14A filed by Mirum Pharmaceuticals Inc.
  • SEC10h
    SEC Form DEF 14A filed by Mirum Pharmaceuticals Inc.
  • INSIDER7d
    SEC Form 4 filed by Ramasastry Saira
  • SEC8d
    SEC Form 144 filed by Mirum Pharmaceuticals Inc.
  • PR10d
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • SEC15d
    Amendment: Mirum Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Mirum Pharmaceuticals Inc.
  • INSIDER37d
    PRESIDENT AND COO Radovich Peter converted options into 30,220 shares and sold $1,519,015 worth of shares (16,515 units at $91.98), increasing direct ownership by 52% to 40,272 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022